GG1

Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance

Retrieved on: 
Donnerstag, Mai 9, 2024
Sale, FDA, CMS, International, Urology, PIN, Food, Travel, Software, TSX, Insurance, S&D, Research, Category 1, Level 1, Consultant, Intelligence, Prostate cancer, Webcast, Prostate, International Financial Reporting Standards, OPPS, GG5, Patient, GG1, Medicare, MRI, G&A, Marketing, Veterans' affairs, Telephone, Food and Drug Administration, Growth, BPH

TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance.

Key Points: 
  • TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance.
  • Earlier this week, Profound announced that 25 TULSA-related scientific research presentations have already been delivered at major medical meetings around the world thus far in 2024.
  • First quarter 2024 revenue increased approximately 3% from $1.86 million in the same three-month period a year ago.
  • First quarter 2024 S&D expenses increased by 15% to approximately $2.4 million, compared with $2.1 million in the first quarter of 2023.

New Study Demonstrates Avenda Health's Unfold AI to Better Predict Focal Therapy Success by 77% Percent as Compared to Standard Methods

Retrieved on: 
Mittwoch, Mai 8, 2024
UCLA, FDA, ECS, AI, American Urological Association, Health, Unfold, MD, PSA, Doctor of Philosophy, Prostate cancer, GG5, Patient, GG1, Physician, AUA, MRI, Biopsy, UCLA Health, Neoplasm, GG, Quality of life, Cryotherapy, Medical imaging

CULVER CITY, Calif., May 8, 2024 /PRNewswire/ -- Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveils the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments. The study titled "Software to Determine Extent of Tumor Margins in Focal Therapy," was presented at the 2024 American Urological Association's (AUA) annual meeting by Wayne Brisbane, MD, assistant professor at UCLA Health. It demonstrated that Unfold AI, Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.

Key Points: 
  • It demonstrated that Unfold AI , Avenda Health's AI-powered cancer mapping technology, was a better predictor of focal therapy success than other factors, including the size or grade of the tumor.
  • In the study, FDA-cleared Unfold AI technology was retrospectively applied to 118 previously untreated men undergoing hemi-gland cryotherapy for prostate cancer ablation.
  • MRI-guided biopsies, both targeted and systematic, were performed before cryotherapy and six months after cryotherapy to assess treatment outcomes.
  • "This more comprehensive approach enhances our ability to predict treatment outcomes and tailor interventions effectively to individual patient needs."

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Donnerstag, März 7, 2024
International, Doctor of Philosophy, PIN, Prostate cancer, Research, Intelligence, Telephone, Marketing, Webcast, TSX, Food, GG5, Sale, Annual report, Travel, BPH, S&D, Consultant, Prostate, Level 1, Food and Drug Administration, Patient, News, Clinical trial, Insurance, G&A, Siemens Healthineers, International Financial Reporting Standards, MRI, Software, GG1, Category 1, Cryptocurrency

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter 2023 revenue increased 60% from approximately $1.3 million in the same three-month period a year ago.
  • G&A expenses for the 2023 fourth quarter increased by 41% to approximately $3.0 million, compared with approximately $2.1 million in the same period in 2022.
  • Fourth quarter 2023 S&D expenses increased by 74% to approximately $2.9 million, compared with $1.7 million in the fourth quarter of 2022.